Recurrence/prognosis estimation using a molecularly positive surgical margin‐based model calls for alternative curative strategies in pIIIA / N2 NSCLC
Molecular Oncology · 2024
DOI: 10.1002/1878-0261.13600 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2024. Verfasst von Li Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences,…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Unit of Radiation Oncology, Chinese Academy of Medical Sciences, Natural Science Innovation and Development Joint Foundation of Shandong, Foundation of Natural Science Foundation of Shandong.
Abstract (Originalsprache)
Stage pIIIA/N2 non‐small cell lung cancer (NSCLC) is primarily treated by complete surgical resection combined with neoadjuvant/adjuvant therapies. However, up to 40% of patients experience tumor recurrence. Here, we studied 119 stage pIIIA/N2 NSCLC patients who received complete surgery plus adjuvant chemotherapy (CT) or chemoradiotherapy (CRT). The paired tumor and resection margin samples were analyzed using next‐generation sequencing (NGS). Although all patients were classified as negative resection margins by histologic methods, NGS revealed that 47.1% of them had molecularly positive surgical margins. Patients who tested positive for NGS‐detected residual tumors had significantly shorter disease‐free survival (DFS) ( P = 0.002). Additionally, metastatic lymph node ratio, erb‐b2 receptor tyrosine kinase 2 ( ERBB2 ) mutations, and SWI/SNF‐related, matrix‐associated, actin‐dependent regulator of chromatin, subfamily a, member 4 ( SMARCA4 ) mutations were also independently associated with DFS. We used these four features to construct a COX model that could effectively estimate recurrence risk and prognosis. Notably, mutational profiling through broad‐panel NGS could more sensitively detect residual tumors than the conventional histologic methods. Adjuvant CT and adjuvant CRT exhibited no significant difference in eliminating locoregional recurrence risk for stage pIIIA/N2 NSCLC patients with molecularly positive surgical margins.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
- Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., China.
- Department of Pathology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
- Department of Radiation Oncology and Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, C…
- Research Unit of Radiation Oncology, Chinese Academy of Medical Sciences, Jinan, China.
- Department of Radiation Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
ORCID-Profile: Yang Xu, Jinming Yu, Shuanghu Yuan
Förderung
- Research Unit of Radiation Oncology, Chinese Academy of Medical Sciences
- Natural Science Innovation and Development Joint Foundation of Shandong
- Foundation of Natural Science Foundation of Shandong
- Academic Promotion Program of Shandong First Medical University
- Taishan Scholars Program
- Natural Science Youth Foundation of Shandong
- China Postdoctoral Science Foundation
- National Natural Science Foundation of China
Zitieren
APA
Li, L., He, K., Zhou, T., Xu, Y., Pang, J., Yu, Q., Gao, Y., Shi, H., Zhu, H., Li, M., Yu, J., & Yuan, S. (2024). Recurrence/prognosis estimation using a molecularly positive surgical margin‐based model calls for alternative curative strategies in pIIIA / N2 NSCLC. Molecular Oncology. https://doi.org/10.1002/1878-0261.13600
Vancouver
Li L, He K, Zhou T, Xu Y, Pang J, Yu Q, et al. Recurrence/prognosis estimation using a molecularly positive surgical margin‐based model calls for alternative curative strategies in pIIIA / N2 NSCLC. Molecular Oncology. 2024. doi:10.1002/1878-0261.13600
BibTeX
@article{Li2024,
author = {Li, Li and He, Kewen and Zhou, Tao and Xu, Yang and Pang, Jiaohui and Yu, Qingxi and Gao, Yongsheng and Shi, Hongjin and Zhu, He and Li, Mengke and Yu, Jinming and Yuan, Shuanghu},
title = {Recurrence/prognosis estimation using a molecularly positive surgical margin‐based model calls for alternative curative strategies in pIIIA / N2 NSCLC},
journal = {Molecular Oncology},
year = {2024},
doi = {10.1002/1878-0261.13600}
}
EUVIMED